Vascular Biogenics (NASDAQ:VBLT) Share Price Passes Below 200 Day Moving Average of $1.41

Vascular Biogenics Ltd. (NASDAQ:VBLTGet Rating) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.41 and traded as low as $0.23. Vascular Biogenics shares last traded at $0.24, with a volume of 3,563,531 shares.

Analysts Set New Price Targets

A number of analysts have weighed in on VBLT shares. HC Wainwright cut shares of Vascular Biogenics from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 20th. StockNews.com started coverage on shares of Vascular Biogenics in a research note on Saturday. They set a “sell” rating on the stock. Chardan Capital cut shares of Vascular Biogenics from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 20th. Oppenheimer cut shares of Vascular Biogenics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 20th. Finally, Jonestrading reaffirmed a “buy” rating and set a $5.00 target price on shares of Vascular Biogenics in a research note on Friday, May 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $4.88.

Vascular Biogenics Stock Down 2.7 %

The company has a market cap of $16.40 million, a P/E ratio of -0.51 and a beta of 0.57. The firm’s 50 day moving average is $1.30 and its two-hundred day moving average is $1.41.

Vascular Biogenics (NASDAQ:VBLTGet Rating) last issued its quarterly earnings data on Tuesday, May 17th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Vascular Biogenics had a negative return on equity of 69.21% and a negative net margin of 4,894.40%. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.20 million. During the same period in the prior year, the firm earned ($0.12) EPS. As a group, research analysts forecast that Vascular Biogenics Ltd. will post -0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Vascular Biogenics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. lifted its holdings in Vascular Biogenics by 49.2% in the first quarter. Advisor Group Holdings Inc. now owns 36,797 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 12,133 shares during the period. Envestnet Asset Management Inc. acquired a new position in Vascular Biogenics in the first quarter valued at $64,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Vascular Biogenics in the fourth quarter valued at $382,000. DLD Asset Management LP acquired a new position in Vascular Biogenics in the fourth quarter valued at $837,000. Finally, Lion Point Capital LP acquired a new position in Vascular Biogenics in the fourth quarter valued at $5,108,000. Institutional investors and hedge funds own 26.15% of the company’s stock.

About Vascular Biogenics

(Get Rating)

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications.

Recommended Stories

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.